Recent Advances and Clinical Outcomes of Kidney Transplantation : Volume 2
Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Specia...
محفوظ في:
| مؤلفون آخرون: | , , |
|---|---|
| التنسيق: | فصل الكتاب |
| منشور في: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | Get Fullteks DOAB: description of the publication |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| LEADER | 07590naaaa2202365uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_69055 | ||
| 005 | 20210501 | ||
| 020 | |a books978-3-03936-408-4 | ||
| 020 | |a 9783039364077 | ||
| 020 | |a 9783039364084 | ||
| 024 | 7 | |a 10.3390/books978-3-03936-408-4 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Cheungpasitporn, Wisit |4 edt | |
| 700 | 1 | |a Thongprayoon, Charat |4 edt | |
| 700 | 1 | |a Leeaphorn, Napat |4 edt | |
| 700 | 1 | |a Cheungpasitporn, Wisit |4 oth | |
| 700 | 1 | |a Thongprayoon, Charat |4 oth | |
| 700 | 1 | |a Leeaphorn, Napat |4 oth | |
| 245 | 1 | 0 | |a Recent Advances and Clinical Outcomes of Kidney Transplantation : Volume 2 |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (270 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a malondialdehyde | ||
| 653 | |a oxidative stress | ||
| 653 | |a new-onset diabetes | ||
| 653 | |a renal transplantation | ||
| 653 | |a BK virus | ||
| 653 | |a BK virus nephropathy | ||
| 653 | |a kidney allograft | ||
| 653 | |a transplantation | ||
| 653 | |a Alport syndrome | ||
| 653 | |a children | ||
| 653 | |a autosomal dominant polycystic kidney disease | ||
| 653 | |a epidemiology | ||
| 653 | |a hospitalization | ||
| 653 | |a kidney transplantation | ||
| 653 | |a subarachnoid hemorrhage | ||
| 653 | |a malignancy | ||
| 653 | |a post-transplant malignancy | ||
| 653 | |a renal cell carcinoma | ||
| 653 | |a meta-analysis | ||
| 653 | |a systematic reviews | ||
| 653 | |a tacrolimus | ||
| 653 | |a C/D-ratio | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a opportunistic infection | ||
| 653 | |a allograft survival | ||
| 653 | |a urological complications | ||
| 653 | |a ureteric stent | ||
| 653 | |a urinary tract infection | ||
| 653 | |a timing of removal | ||
| 653 | |a living donor | ||
| 653 | |a ethnicity | ||
| 653 | |a age | ||
| 653 | |a obesity | ||
| 653 | |a genetic relationship donor/recipient | ||
| 653 | |a atypical hemolytic uremic syndrome | ||
| 653 | |a eculizumab | ||
| 653 | |a glucose intolerance | ||
| 653 | |a insulin secretion | ||
| 653 | |a insulin resistance | ||
| 653 | |a oral glucose tolerance test | ||
| 653 | |a healthy subject | ||
| 653 | |a hyperchloremia | ||
| 653 | |a kidney graft dysfunction | ||
| 653 | |a living donor kidney transplantation | ||
| 653 | |a Uropathogenic E. coli | ||
| 653 | |a UPEC | ||
| 653 | |a phylogeny | ||
| 653 | |a genomics | ||
| 653 | |a antibiotic resistance | ||
| 653 | |a virulence traits | ||
| 653 | |a night-time renal transplantation | ||
| 653 | |a graft survival | ||
| 653 | |a patient survival/outcome | ||
| 653 | |a surgical complications | ||
| 653 | |a acute rejection | ||
| 653 | |a lymphocyte | ||
| 653 | |a CD45RC | ||
| 653 | |a Belatacept | ||
| 653 | |a cardiovascular high risk | ||
| 653 | |a outcome | ||
| 653 | |a machine perfusion | ||
| 653 | |a organ preservation | ||
| 653 | |a temperature | ||
| 653 | |a hypothermic | ||
| 653 | |a normothermic | ||
| 653 | |a transplant | ||
| 653 | |a proton-pump inhibitors | ||
| 653 | |a iron | ||
| 653 | |a iron deficiency | ||
| 653 | |a polyomavirus | ||
| 653 | |a BKV | ||
| 653 | |a kidney | ||
| 653 | |a glomerulus | ||
| 653 | |a BKVAN | ||
| 653 | |a nephropathy | ||
| 653 | |a fluid management | ||
| 653 | |a delayed graft function | ||
| 653 | |a goal-directed fluid therapy | ||
| 653 | |a calcineurin inhibitor nephrotoxcity | ||
| 653 | |a C/D ratio | ||
| 653 | |a tacrolimus metabolism | ||
| 653 | |a ADPKD | ||
| 653 | |a native nephrectomy | ||
| 653 | |a patient outcome | ||
| 653 | |a perioperative complications | ||
| 653 | |a epidermal growth factor | ||
| 653 | |a creatinine | ||
| 653 | |a graft failure | ||
| 653 | |a renal transplantation. | ||
| 653 | |a new onset diabetes after renal transplantation | ||
| 653 | |a single nucleotide polymorphisms | ||
| 653 | |a n/a | ||
| 653 | |a urinary biomarkers | ||
| 653 | |a α-GST | ||
| 653 | |a π-GST | ||
| 653 | |a nephrotoxicity | ||
| 653 | |a urinary excretion of N1-methylnicotinamide | ||
| 653 | |a mortality | ||
| 653 | |a niacin status | ||
| 653 | |a dietary intake | ||
| 653 | |a tryptophan | ||
| 653 | |a vitamin B3 | ||
| 653 | |a Kidney transplant | ||
| 653 | |a vitamin C | ||
| 653 | |a cancer mortality | ||
| 653 | |a oxidative stress. | ||
| 653 | |a mycophenolic acid | ||
| 653 | |a immunosuppression | ||
| 653 | |a plasmapheresis | ||
| 653 | |a oxalate | ||
| 653 | |a hyperoxaluria | ||
| 653 | |a kidney transplant recipients | ||
| 653 | |a post-transplantation diabetes mellitus | ||
| 653 | |a all-cause mortality | ||
| 653 | |a cardiovascular mortality | ||
| 653 | |a infectious mortality | ||
| 653 | |a magnesium | ||
| 653 | |a hypomagnesaemia | ||
| 653 | |a cancer | ||
| 653 | |a kidney transplant | ||
| 653 | |a survival | ||
| 653 | |a living kidney donation | ||
| 653 | |a living-donor kidney transplantation | ||
| 653 | |a beliefs | ||
| 653 | |a inequity | ||
| 653 | |a ischemia reperfusion injury | ||
| 653 | |a innate immune system | ||
| 653 | |a adaptive immune system | ||
| 653 | |a apoptosis | ||
| 653 | |a necrosis | ||
| 653 | |a hypoxic inducible factor | ||
| 653 | |a endothelial dysfunction | ||
| 653 | |a proton pump inhibitor | ||
| 653 | |a transplant rejection | ||
| 653 | |a GFR | ||
| 653 | |a insulin-like growth factor 1 | ||
| 653 | |a growth hormone | ||
| 653 | |a muscle mass | ||
| 653 | |a patient survival | ||
| 653 | |a physical activity | ||
| 653 | |a renal transplant recipients | ||
| 653 | |a kidney transplant (KT) | ||
| 653 | |a donor-specific antibodies (DSA) | ||
| 653 | |a C3d-binding assay | ||
| 653 | |a antibody-mediated rejection (AMR) | ||
| 653 | |a arsenic | ||
| 653 | |a diet | ||
| 653 | |a fish consumption | ||
| 653 | |a post-transplant diabetes mellitus | ||
| 653 | |a N1-methyl-2-pyridone-5-carboxamide | ||
| 653 | |a N1-methylnicotinamide | ||
| 653 | |a urinary excretion | ||
| 653 | |a kidney function | ||
| 653 | |a biomarker | ||
| 653 | |a branched chain amino acids | ||
| 653 | |a posttransplant diarrhea | ||
| 653 | |a methanogenesis | ||
| 653 | |a Methanosphaera stadtmanae | ||
| 653 | |a mucins | ||
| 653 | |a sulfate-reducing bacteria | ||
| 653 | |a acute humoral rejection | ||
| 653 | |a first-line therapy | ||
| 653 | |a outcomes | ||
| 653 | |a proteasome inhibitor | ||
| 653 | |a renal transplant | ||
| 653 | |a transplant recipients | ||
| 653 | |a calcineurin inhibitors | ||
| 653 | |a FK506 | ||
| 653 | |a pharmacokinetic | ||
| 653 | |a fast tacrolimus metabolizers | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2824 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/69055 |7 0 |z DOAB: description of the publication |